Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | WNT1 | P04628 | 1/20 | 0.35 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.35 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | BCR | P11274 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16775881 | 0.90 | TRPV1 (0.43) | ROCK2TRPV1 | |
| SCHEMBL16775848 | 0.89 | CPT2 (0.37) | ROCK2TRPV1CA9 | |
| SCHEMBL16775945 | 0.88 | PRKCI (0.39) | ROCK2TRPV1ABL1BCR | |
| SCHEMBL16775830 | 0.88 | CNR2 (0.37) | ROCK2TRPV1 | |
| SCHEMBL16775822 | 0.87 | TRPV1 (0.37) | ROCK2TRPV1CA9 | |
| SCHEMBL16776144 | 0.86 | KMT2A (0.44) | RPS6KA2CA9 | |
| SCHEMBL16776146 | 0.85 | HTR2C (0.48) | ABL1BCR | |
| SCHEMBL16775869 | 0.85 | TRPV1 (0.42) | TRPV1ABL1BCR | |
| SCHEMBL20633013 | 0.84 | HTR2C (0.38) | ROCK2TRPV1PRMT3CA9 | |
| SCHEMBL16775840 | 0.84 | PIKFYVE (0.37) | TRPV1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | ROCK2 3343/4885TRPV1 3670/4885WNT1 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.